Newswire (Published: Friday, April 14, 2017, Received: Friday, April 7, 2017, 3:41:57 AM CDT)

Word Count: 594

Study Data from Tokyo Medical University Update Knowledge of Prostate Cancer (Development of a Nomogram for Predicting Severe Neutropenia Associated With Docetaxel-Based Chemotherapy in Patients With Castration-Resistant Prostate Cancer)

By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in Oncology - Prostate Cancer. According to news reporting from Tokyo, Japan, by NewsRx journalists, research stated, "We analyzed 112 patients with castration-resistant prostate cancer (CRPC) treated with docetaxel-based chemotherapy to identify risk factors for severe neutropenia (SN) in the first cycle of chemotherapy. Age and baseline neutrophil counts were significant independent risk factors."

The news correspondents obtained a quote from the research from Tokyo Medical University, "Based on the risk factors, we developed a nomogram for predicting SN in the first cycle of docetaxel-based chemotherapy for patients with CRPC. Neutropenia is a major adverse event of docetaxel-based chemotherapy. The present study was undertaken to evaluate the incidence of neutropenia and to develop a nomogram for predicting Grade 4 neutropenia during the first cycle of docetaxel-based chemotherapy in patients with castration-resistant prostate cancer (CRPC). This study included 112 patients with CRPC treated with docetaxel-based systemic chemotherapy. We evaluated the incidence and risk factors for Grade 4 neutropenia in the first cycle of chemotherapy. Sixty-two of 112 patients (55.4%) developed Grade 4 neutropenia in the first cycle of docetaxel-based chemotherapy. There were significant differences in age, baseline white blood cell count, and baseline neutrophil count between patients with non-Grade 4 neutropenia and those with Grade 4 neutropenia in univariate analyses. The serum prostate-specific antigen level, hemoglobin level, creatinine, albumin, Eastern Cooperative Oncology Group performance status, metastatic sites, extent of disease, and history of external beam radiotherapy to the prostate were not significantly different between the 2 groups. Multivariate logistic regression analysis showed that age (odds ratio [OR], 1.08; P = .019) and baseline neutrophil counts (OR, 0.79; P =.045) were significant independent risk factors for severe neutropenia. A nomogram and a calibration plot on the basis of these results were developed from a multivariate logistic regression analysis to predict the probability of Grade 4 neutropenia. Age and baseline neutrophil counts were significant independent risk factors for Grade 4 neutropenia."

According to the news reporters, the research concluded: "The nomogram to predict it provides useful information for the management of patients with CRPC treated with docetaxel chemotherapy."

For more information on this research see: Development of a Nomogram for Predicting Severe Neutropenia Associated With Docetaxel-Based Chemotherapy in Patients With Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017;15(1):176-181. Clinical Genitourinary Cancer can be contacted at: Cig Media Group, Lp, 3500 Maple Avenue, Ste 750, Dallas, TX 75219-3931, USA. (Elsevier - www.elsevier.com; Clinical Genitourinary Cancer - www.journals.elsevier.com/clinical-genitourinary-cancer/)

Our news journalists report that additional information may be obtained by contacting J. Nakashima, Tokyo Med Univ, Dept. of Urol, Tokyo, Japan. Additional authors for this research include J. Nakashima, T. Sugihara, I. Takizawa, T. Gondo, Y. Nakagami, Y. Horiguchi, Y. Ohno, K. Namiki, M. Ohori and M. Tachibana (see also Oncology - Prostate Cancer).

Keywords for this news article include: Tokyo, Japan, Asia, Hemic and Lymphatic Diseases and Conditions, Hematologic Diseases and Conditions, Leukocyte Diseases and Conditions, Hemic and Immune Systems, Risk and Prevention, Drugs and Therapies, Leukocyte Disorders, Prostatic Neoplasms, Agranulocytosis, Prostate Cancer, Granulocytes, Chemotherapy, Blood Cells, Neutrophils, Neutropenia, Immunology, Phagocytes, Hematology, Leukopenia, Oncology, Tokyo Medical University.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

Tokyo Medical University

Places

Eastern Asia
North America
Japan
United States
Americas
Asia
Texas
Tokyo
Dallas

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
      Treatments and Therapies
            Chemotherapy